GENERAL25 Sept 2026
Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy
Dr Lal PathLabs has bought a 70 per cent stake in SN Genelab for ₹168 crore. SN Genelab is a leader in genomics testing in India. This deal should build Dr Lal's genomics skills and widen its advanced diagnostics range, so patients may see more advanced tests on offer. If you run a diagnostic lab or refer tests for patients, watch how this changes your local options.
Key Statutory Highlights
- Dr Lal PathLabs acquired a 70 per cent stake in SN Genelab for ₹168 crore.
- SN Genelab is a leader in genomics testing in India.
- The acquisition is expected to strengthen Dr Lal's genomics expertise and broaden its advanced diagnostics portfolio.
Actionable Advice for Taxpayers / Founders:If you run a diagnostics business or refer tests for patients, keep an eye on how this deal changes the advanced testing options available around you, and compare them with your current lab partner before you commit.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: